Citalopram for agitation in Alzheimer's disease: design and methods
Lea T Drye,Zahinoor Ismail,Anton P Porsteinsson,Paul B Rosenberg,Daniel Weintraub,Christopher Marano,Gregory Pelton,Constantine Frangakis,Peter V Rabins,Cynthia A Munro,Curtis L Meinert,D P Devanand,Jerome Yesavage,Jacobo E Mintzer,Lon S Schneider,Bruce G Pollock,Constantine G Lyketsos,CitAD Research Group,Constantine Lyketsos,Dimitri Avramopoulos,Cynthia Munro,Peter Rabins,Anne Roche,Dave Shade,Curtis Meinert,Anne Shanklin Casper,Lea Drye,Gabrielle Jenkins,Hao-Min Pan,Susan Tonascia,Ozlem Topaloglu,Vijay Vaidya,Laurie Ryan,Paul Rosenberg,Julia Pedroso,Lynn Smith,Martin Steinberg,Karine Cunqueiro,Jacobo Mintzer,Crystal Flynn-Longmire,Amy Gandy,Markeeta Hatchell,Shenequia Lucas,Olga Brawman-Mintzer,Thad Modlin,Samantha Russell,Elizabeth Safrit,Marilyn Stuckey,Rhonda Weichsel,Arthur Williams,Jamie Czerniakowski,Suzanne DiFilippo,Eugenia Mamikonyan,Joel Streim,Anton Porsteinsson,Kelly Cosman,Bonnie Goldstein,Saleem Ismail,Nancy Kowalski,Tim Romeo,Susan Salem-Spencer,Kelly Stear,Wes Ashford,Karen Bratcher,Leah Friedman,Gerald Georgette,Emily Gere,Ellen Kim,Jeff Newell,Vyjeyanthi Periyakoil,Arthur Traum,Alda Vicencio,Deryl Wicks,Dielle Miranda,Benoit H Mulsant,Minh-Quan Nguyen,Tarek Rajji,Maurcio Becerra,Karen Dagerman,Sonia Pawluczyk,Bryan Spann,Liberty Teodoro
DOI: https://doi.org/10.1016/j.jalz.2011.01.007
Abstract:Background: Agitation is one of the most common neuropsychiatric symptoms of Alzheimer's disease (AD), and is associated with serious adverse consequences for patients and caregivers. Evidence-supported treatment options for agitation are limited. The citalopram for agitation in Alzheimer's disease (CitAD) study was designed to evaluate the potential of citalopram to ameliorate these symptoms. Methods: CitAD is a randomized, double-masked, placebo-controlled multicenter clinical trial, with two parallel treatment groups assigned in a 1:1 ratio and randomization stratified by clinical center. The study included eight recruiting clinical centers, a chair's office, and a coordinating center located in university settings in the United States and Canada. A total of 200 individuals having probable AD with clinically significant agitation and without major depression were recruited for this study. Patients were randomized to receive citalopram (target dose of 30 mg/d) or matching placebo. Caregivers of patients in both treatment groups received a structured psychosocial therapy. Agitation was compared between treatment groups using the NeuroBehavioral Rating Scale and the AD Cooperative Study- Clinical Global Impression of Change, which are the primary outcomes. Functional performance, cognition, caregiver distress, and rates of adverse and serious adverse events were also measured. Conclusion: The authors believe the design elements in CitAD are important features to be included in trials assessing the safety and efficacy of psychotropic medications for clinically significant agitation in AD.